Bayer Pharmaceuticals

What Bayer Pharmaceuticals does

Bayer Pharmaceuticals is the pharmaceutical division of Bayer AG, a publicly listed German multinational (Frankfurt Stock Exchange: BAYZN) headquartered in Leverkusen. It develops, manufactures, and commercializes prescription pharmaceuticals across cardiology, oncology, women's health, ophthalmology, hematology, and rare diseases, serving patients in 93 countries through direct sales, healthcare distribution networks, and pharmacy channels. Its revenue model is anchored by global product sales, supplemented by licensing, partnership, and milestone-based income from more than 30 active collaborations with academic institutions, biotechnology companies, and technology partners.

The division's technology portfolio is broad and modality-diversified, spanning approximately 55% small molecules and 45% biologics and advanced therapies across 40 active programs (31 in clinical development as of January 2026). Core platforms include precision medicine, cell and gene therapy (gene therapy, cell therapy, gene editing), AAV therapeutics, PROTACs, RNA-targeting small molecules, targeted alpha therapy, chemoproteomics, immuno-oncology, and diagnostic imaging. AI is integrated across the value chain — from target identification and biomarker discovery to clinical trial optimization and imaging analysis — with senior AI/ML and biologics leadership embedded in the organization. Notable assets include the reference-listed drug Vitrakvi (larotrectinib) for TRK fusion cancers and sevabertinib, an ERBB2-mutant NSCLC candidate under FDA Priority Review arising from the Broad Institute collaboration.

Bayer Pharmaceuticals goes to market through enterprise field sales targeting healthcare institutions and specialty pharmacies, supported by healthcare-professional engagement, scientific publications, medical conferences, and patient information platforms. Recent strategic activity has centered on partnerships for precision oncology (Broad Institute, Lung Cancer Research Foundation), the 2022 acquisition of Vividion Therapeutics for covalent-binding drug discovery, and R&D expansion in Beijing (2024) to participate in China's strategic medical device and pharmaceutical ecosystem. Bayer AG's board-level oversight includes Bill Anderson, Judith Hartmann, Stefan Oelrich, Heike Prinz, Rodrigo Santos, and Julio Triana, with Dieter Weinand identified as president and CEO in the division's leadership data.

Name

Bayer Pharmaceuticals

Legal name

Bayer AG

Website

https://pharma.bayer.com

Company type

Public

Founded year

1863

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Bayer Pharmaceuticals, the pharma division of Bayer AG, develops and commercializes prescription drugs across cardiology, oncology, women's health, ophthalmology, and rare diseases in 93 countries. It operates a 40-program pipeline spanning small molecules, biologics, cell and gene therapies, and AI-augmented discovery.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541), Medical Equipment and Supplies Manufacturing (33911)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Oncology Specialty Pharmaceuticals (HLAIACAA), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Prescription pharmaceuticals
• Oncology therapeutics
• Cell and gene therapy
• Precision medicine
• Cardiovascular treatments

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Bayer Pharmaceuticals generates revenue through the sale of innovative prescription pharmaceuticals across therapeutic areas including cardiology, oncology, women's health, hematology, and rare diseases. The company maintains a robust pipeline with 40 active programs and serves patients in 93 countries.
2. Licensing and Partnership Revenue: Strategic partnerships and collaborations that may include licensing agreements, co-development arrangements, and milestone payments. Bayer maintains more than 30 active partnerships with academic institutions, biotechnology companies, and technology partners.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Bayer Pharmaceuticals develops, manufactures, and commercializes prescription medicines across five therapeutic areas: cardiovascular, oncology, women's health, ophthalmology, and rare disease. Its portfolio is balanced between small molecules (~55%) and biologics/advanced therapies (~45%), with 40 active pipeline programs and a stated focus on precision medicine, cell and gene therapy, and targeted oncology.

Product overview

Bayer Pharmaceuticals is a global pharmaceutical company with 148 years of experience serving 93 countries. The company operates a diversified portfolio centered around a robust clinical pipeline of 40 active programs (as of January 2026), with approximately 55% small molecules and 45% biologics and advanced therapies. The core offering encompasses multiple therapeutic areas including Oncology (treatments for gastrointestinal stromal tumor, breast cancer, kidney cancer, liver cancer, prostate cancer, TRK fusion cancer, thyroid cancer, NSCLC), Cardiovascular and Renal Health (heart attack, thrombosis, stroke, atrial fibrillation, heart failure, high blood pressure, chronic kidney disease), Women's Health (contraception, menopause, endometriosis, heavy menstrual bleeding, acne), Eye Conditions (age-related macular degeneration, diabetic macular edema), Hematology, and Healthy Aging. Bayer's innovation platform includes Cell and Gene Therapy (gene therapy, cell therapy, gene editing), Radiology and Diagnostics, AAV Therapeutics, Stem Cell Research, PROTAC Technology, RNA-targeting Small Molecules, and Diagnostic Imaging. The company leverages AI across its pharmaceutical value chain for accelerated drug discovery and development.

Differentiator

Problem solved

Functional benefit

Brands

• Vitrakvi: Larotrectinib capsules for treatment of solid tumors with NTRK gene fusion, reference listed drug for which Bayer Healthcare Pharmaceuticals holds the original approval.

Products and services

• Pharmaceuticals Portfolio
• Oncology Therapeutics
• Vitrakvi (Larotrectinib)
• Women's Health Treatments
• Cardiovascular and Renal Treatments
• Ophthalmology Treatments
• Rare Disease Treatments
• Cell and Gene Therapy Platform
• Radiology and Diagnostic Imaging Agents

Quantifiable outcome

• 40 active programs in pipeline as of January 2026
• +3 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature9 records

Partnerships

Three partnerships are on record, tiered core and regional.

• Lung Cancer Research FoundationcoreStrategic or Co-development Partner · 6 January 2026Lung Cancer Research Foundation awarded grants including collaboration with Bayer Pharmaceuticals on HER2-mutant lung cancer research. The partnership is part of a $5.2 million grant cycle with 21 grant awards, contributing to the organization's active research portfolio exceeding $21 million.
• Broad InstitutecoreStrategic or Co-development Partner · 17 October 2025Scientists at the Broad Institute and Bayer Pharmaceuticals developed drug candidate sevabertinib aimed at treating non-small cell lung cancers with ERBB2 mutations. The drug is currently under Priority Review at the FDA, with potential approval based on ongoing clinical trial results. This represents a significant academic-industry collaboration in targeted oncology.
• Beijing Medical Device IndustryregionalStrategic or Co-development Partner · 1 January 2024Bayer Pharmaceuticals established R&D facilities in Beijing as part of China's strategic medical device and pharmaceutical ecosystem. Beijing has designated its medical device industry as a strategic priority under a 2024-2026 Action Plan, targeting growth to over RMB 50 billion (US$7.4 billion).

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Sanofi: European-headquartered multinational with overlapping specialty care, rare disease (Genzyme), and oncology ambitions. Comparable scale and similar global distribution footprint.
• Merck & Co. (MSD): Major oncology competitor (Keytruda) and cardiovascular player with similar global commercial scale. Comparable in pipeline diversification across specialty and primary care.
• Roche: Global pharma leader with deep oncology, diagnostics, and specialty care portfolios. Competes directly with Bayer in oncology and women's health, and overlaps in diagnostic imaging/diagnostics integration.
• Pfizer: Global branded pharmaceutical company with comparable diversified therapeutic areas (oncology, cardiovascular, rare disease) and similar biologics/small-molecule mix. Direct competitor in cardiology and oncology markets where both companies operate.
• Novartis: Major Swiss multinational with overlapping franchises in cardiovascular, oncology, and cell/gene therapy (Kymriah, Zolgensma). Comparable pipeline scale and innovation model make Novartis one of the closest comparables.
• AstraZeneca: Direct competitor in oncology (NSCLC, breast, prostate) and cardiovascular disease, with similar emphasis on targeted therapies, antibody-drug conjugates, and AI-enabled clinical development.
• Bristol-Myers Squibb: Specialty pharma competitor in cardiovascular (Eliquis competing with Xarelto) and oncology (immuno-oncology overlaps Bayer's stated strategy). Directly comparable R&D intensity.
• GSK: UK-based pharma with established vaccines, specialty, and oncology presence. Competes with Bayer in women's health and select oncology indications; similar enterprise-scale and pipeline breadth.

Broad incumbents

• Eli Lilly: Large incumbent pharma expanding aggressively in oncology and cardiometabolic; competes with Bayer in diabetes/obesity adjacency and precision oncology. Comparable pipeline diversification.
• Johnson & Johnson Innovative Medicine: Diversified pharma division with strong oncology and cardiovascular franchises. Comparable global scale and innovation model, though broader portfolio includes medtech and consumer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/bayerpharma
• Facebookfacebook.com/pharma.bayer

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bayer Pharmaceuticals